Depo-Provera. Controversial contraceptive wins approval from FDA panel.
Stone
R
R
D000328:Adult; D001943:Breast Neoplasms / Q000139:chemically induced; D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007880:Legislation, Drug; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D010024:Osteoporosis / Q000139:chemically induced; D014481:United States; D014486:United States Food and Drug Administration; D014594:Uterine Neoplasms / Q000517:prevention & control
D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone